Artwork

Το περιεχόμενο παρέχεται από το AWS Startups. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον AWS Startups ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.
Player FM - Εφαρμογή podcast
Πηγαίνετε εκτός σύνδεσης με την εφαρμογή Player FM !

#86, Unleashing AI's Power to Design Drugs with Medicinal Chemistry, Yann Gaston-Mathé from Iktos

40:05
 
Μοίρασέ το
 

Manage episode 416868509 series 3291628
Το περιεχόμενο παρέχεται από το AWS Startups. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον AWS Startups ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

Imagine being able to design novel drug molecules with the same ease as typing words into a computer, and being given the instructions into how to synthesize that molecule in the lab. That's the incredible potential of Iktos, our guest on today's episode of the AWS Health Innovation Podcast hosted by Alex Merwin, Head of Growth for Healthcare & Life Sciences Startups at AWS, and featuring Yann Gaston-Mathé, the Founder & CEO of Iktos.

1. How is Iktos revolutionizing the field of drug discovery with AI?

  • Iktos' groundbreaking approach harnesses deep generative AI models trained on vast molecular databases to automatically design novel, optimized molecules for drug discovery challenges. This innovative technology promises to accelerate pharmaceutical R&D by rapidly generating promising molecular candidates tailored to specific therapeutic targets.

2. What is the unconventional journey of Iktos' founder, Yann Gaston-Mathé?

  • Yann Gaston-Mathé, Iktos' founder and CEO, followed an atypical path, publishing his first academic paper at over 40 after diverse experiences spanning engineering, biology, consulting, and entrepreneurship before embracing the AI innovation that became Iktos.

3. What is Iktos' integrated AI-robotics platform, and how does it provide a competitive advantage?

  • Iktos developed an integrated AI-robotics platform to automate molecular synthesis and generate real-world data for active learning, recursively improving its AI models' performance through continuous feedback loops, a key competitive advantage.

4. How has Iktos demonstrated the transformative impact of its technology in drug discovery?

  • Leveraging its AI expertise, Iktos successfully optimized drug candidates for a Japanese pharma client, meeting 7-8 out of 8 success criteria within 12 months, demonstrating the transformative potential of its technology in accelerating drug discovery pipelines.

5. How does Iktos foster a culture of multidisciplinary innovation?

  • Iktos cultivates a collaborative culture promoting cross-team knowledge sharing and brainstorming between AI, computational chemistry, and medicinal chemistry experts, fostering multidisciplinary innovation at the convergence of these fields.

Learn more about Iktos and their AI-driven drug discovery solutions on their website.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

  continue reading

116 επεισόδια

Artwork
iconΜοίρασέ το
 
Manage episode 416868509 series 3291628
Το περιεχόμενο παρέχεται από το AWS Startups. Όλο το περιεχόμενο podcast, συμπεριλαμβανομένων των επεισοδίων, των γραφικών και των περιγραφών podcast, μεταφορτώνεται και παρέχεται απευθείας από τον AWS Startups ή τον συνεργάτη της πλατφόρμας podcast. Εάν πιστεύετε ότι κάποιος χρησιμοποιεί το έργο σας που προστατεύεται από πνευματικά δικαιώματα χωρίς την άδειά σας, μπορείτε να ακολουθήσετε τη διαδικασία που περιγράφεται εδώ https://el.player.fm/legal.

Imagine being able to design novel drug molecules with the same ease as typing words into a computer, and being given the instructions into how to synthesize that molecule in the lab. That's the incredible potential of Iktos, our guest on today's episode of the AWS Health Innovation Podcast hosted by Alex Merwin, Head of Growth for Healthcare & Life Sciences Startups at AWS, and featuring Yann Gaston-Mathé, the Founder & CEO of Iktos.

1. How is Iktos revolutionizing the field of drug discovery with AI?

  • Iktos' groundbreaking approach harnesses deep generative AI models trained on vast molecular databases to automatically design novel, optimized molecules for drug discovery challenges. This innovative technology promises to accelerate pharmaceutical R&D by rapidly generating promising molecular candidates tailored to specific therapeutic targets.

2. What is the unconventional journey of Iktos' founder, Yann Gaston-Mathé?

  • Yann Gaston-Mathé, Iktos' founder and CEO, followed an atypical path, publishing his first academic paper at over 40 after diverse experiences spanning engineering, biology, consulting, and entrepreneurship before embracing the AI innovation that became Iktos.

3. What is Iktos' integrated AI-robotics platform, and how does it provide a competitive advantage?

  • Iktos developed an integrated AI-robotics platform to automate molecular synthesis and generate real-world data for active learning, recursively improving its AI models' performance through continuous feedback loops, a key competitive advantage.

4. How has Iktos demonstrated the transformative impact of its technology in drug discovery?

  • Leveraging its AI expertise, Iktos successfully optimized drug candidates for a Japanese pharma client, meeting 7-8 out of 8 success criteria within 12 months, demonstrating the transformative potential of its technology in accelerating drug discovery pipelines.

5. How does Iktos foster a culture of multidisciplinary innovation?

  • Iktos cultivates a collaborative culture promoting cross-team knowledge sharing and brainstorming between AI, computational chemistry, and medicinal chemistry experts, fostering multidisciplinary innovation at the convergence of these fields.

Learn more about Iktos and their AI-driven drug discovery solutions on their website.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

  continue reading

116 επεισόδια

Όλα τα επεισόδια

×
 
Loading …

Καλώς ήλθατε στο Player FM!

Το FM Player σαρώνει τον ιστό για podcasts υψηλής ποιότητας για να απολαύσετε αυτή τη στιγμή. Είναι η καλύτερη εφαρμογή podcast και λειτουργεί σε Android, iPhone και στον ιστό. Εγγραφή για συγχρονισμό συνδρομών σε όλες τις συσκευές.

 

Οδηγός γρήγορης αναφοράς